Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Jang Ik Cho"'
Autor:
Silva A, Arslanian, Tamara, Hannon, Philip, Zeitler, Lily C, Chao, Claudia, Boucher-Berry, Margarita, Barrientos-Pérez, Elise, Bismuth, Sergio, Dib, Jang Ik, Cho, David, Cox, Chandan, Saha
Publikováno v:
The New England journal of medicine. 387(5)
The incidence of type 2 diabetes mellitus is increasing among youths. Once-weekly treatment with dulaglutide, a glucagon-like peptide-1 receptor agonist, may have efficacy with regard to glycemic control in youths with type 2 diabetes.In a double-bli
Autor:
SILVA A. ARSLANIAN, JANG IK CHO, TAMARA S. HANNON, PHILIP ZEITLER, LILY CHAO, MARGARITA BARRIENTOS, CLAUDIA C. BOUCHER-BERRY, ELISE BISMUTH, SERGIO A. DIB, DAVID COX
Publikováno v:
Diabetes. 71
AWARD-PEDS was a Phase 3 trial to assess the efficacy and safety of dulaglutide (DU) , a once-weekly GLP-1 receptor agonist, in youth (10 to In conclusion, in youth with inadequately controlled T2D treated with or without metformin and/or basal insul
Autor:
Debra Ignaut, Jang Ik Cho, John Elpers, Farai Chigutsa, Carolina Piras de Oliveira, Ralf Klask
Publikováno v:
Hand in Hand zum Ziel – einfach.besser.messbar www.diabeteskongress.de.
Autor:
Carolina Piras De Oliveira, Rosirene Paczkowski, Jang Ik Cho, Rattan Juneja, Jiat Ling Poon, Emily R Hankosky, Debra A Ignaut, Alfonso Ponce-Ibarra
Publikováno v:
Hand in Hand zum Ziel – einfach.besser.messbar www.diabeteskongress.de.
Autor:
Moshe Phillip, Rong Liu, Debra A. Ignaut, Mark Warren, Barry Horowitz, Farai Chigutsa, Janet Tobian, Jang Ik Cho, Thomas Hardy, Bruce W. Bode
Publikováno v:
Diabetes, Obesity & Metabolism
Aim To evaluate the efficacy and safety of ultra rapid lispro (URLi) versus lispro (Humalog®) in people with type 1 diabetes on continuous subcutaneous insulin infusion (CSII). Materials and Methods This was a phase 3, 16‐week, treat‐to‐target
Autor:
Juliana M. Bue-Valleskey, Leslie J. Klaff, Nanette C. Schloot, Janet Tobian, Mary Anne Dellva, Jang Ik Cho, Dominik Dahl, Junnosuke Miura
Publikováno v:
Diabetes Therapy
Introduction The PRONTO-T1D study, which evaluated the efficacy and safety of ultra rapid lispro (URLi) versus lispro in adults with type 1 diabetes (T1D), met the primary endpoint of noninferiority of HbA1c change from baseline compared to lispro at
Autor:
Andrea Goldyn, Rosirene Paczkowski, Carolina Piras De Oliveira, Debra A. Ignaut, Emily R. Hankosky, Jiat Ling Poon, Jang Ik Cho
Publikováno v:
Diabetes. 70
Background: In PRONTO-Pump-2, a Phase 3, 16-week, randomized, double-blind clinical trial in patients with type 1 diabetes on continuous subcutaneous insulin infusion, ultra rapid lispro (URLi) showed superior postprandial glucose control and noninfe
Publikováno v:
Diabetes. 70
Background: In phase 3 trials, ultra rapid lispro (URLi) showed superior postprandial glucose control and non-inferior HbA1c reduction compared to Humalog® (Lispro). However, infusion site reactions (combined; ISRs) were more frequent with URLi. Met
Autor:
Debra A. Ignaut, Carolina Piras De Oliveira, Rosirene Paczkowski, Rattan Juneja, Jiat Ling Poon, Jang Ik Cho, Emily R. Hankosky
Publikováno v:
Diabetes. 70
Background: In PRONTO-Pump-2, a Phase 3, 16-week, randomized, double-blind clinical trial in patients with type 1 diabetes on continuous subcutaneous insulin infusion (CSII), ultra rapid lispro (URLi; a novel mealtime insulin), showed superior postpr
Publikováno v:
PLoS ONE, Vol 9, Iss 6, p e99085 (2014)
BackgroundThe possible effects of dairy product intake against obesity have been suggested in animal studies; however, the association is still not well established in epidemiological studies. Few studies in Asian countries with relatively low intake
Externí odkaz:
https://doaj.org/article/e49e731c094e480d94fe3a08af544f86